Life Healthcare Group Holdings Limited · JSE:LHC
Life Healthcare — Investor Presentation (March 2018)
14 slides from Life Healthcare's investor presentation, Mar 27, 2018
Slide 1: Life Healthcare Pre-Close Investor Call
LIFE HEALTHCARE PRE-CLOSE INVESTOR CALL SHREY VIRANNA - GROUP CEO PIETER VAN DER WESTHUIZEN - GROUP CFO 27 MARCH 2018 1
Slide 2: Outlook as per 2017 Annual Results
OUTLOOK AS PER 2017 ANNUAL RESULTS SHREY VIRANNA GROUP CEO 2
Slide 3: 2018 Outlook
2018 Outlook FY 2017 Results Southern Africa: • Return to positive PPD growth of c. 1% • Addition of 120 acute hospital beds Alliance Medical: • Continued growth in underlying diagnostic business in the UK, although pricing pressure being experienced in the mobile division. Opening of the first Comm
Slide 4: Operational Update – H1 2018
OPERATIONAL UPDATE – H1 2018 SHREY VIRANNA GROUP CEO 4
Slide 5: Operational review: Southern Africa
Operational review Southern Africa Estimated Range 30 Sept 31 Mar 31 Mar 2018 2017 2017 PPD growth 1.5% – 2.2% (1.7%) (1.0%) Occupancy 68.5% to 70.0% 70.0% 68.4% Additional beds c. 90 133 82 • PPD Growth: - Return to positive PPD growth - Exceeding our end of FY2017 expectations • Occupancies: - Occ
Slide 6: Operational Review: Southern Africa
Operational Review Southern Africa • 2018 Price increase: − c. 5.3% • 2018 Average Salary Increase: − c. 6.5% • Complementary Services: − Continued good revenue growth across all complementary business lines (> 10%) • Healthcare Services: − Strong revenue growth in the context of a lower margin • He
Slide 7: Operational Review: Alliance Medical
Operational Review International Alliance Medical: • Good overall operational performance across the different territories • UK (c. 50% of revenue): − Continue to see strong PET-CT volume growth − Roll-out of the PET-CT static programme continued during H1 − Opened the first UK Community Diagnostic
Slide 8: Operational Review: Poland and India
Operational Review International Poland (Scanmed): • Strong operational performance • 4 year NFZ contracts signed covering 95% of the Scanmed business at generally better average pricing of 4% • Improved integration and efficiency programmes have resulted in an improved EBITDA margin India (Max Heal
Slide 9: Financial Update – H1 2018
FINANCIAL UPDATE - H1 2018 PIETER VAN DER WESTHUIZEN GROUP CFO 9
Slide 10: Financial review: Southern Africa
Financial review Southern Africa Estimated Range 30 Sept 31 Mar 31 Mar 2018 2017 2017 Revenue % growth 8.0% to 10.0% 4.3% 4.7% Normalised EBITDA margin % 24.5% to 25.5% 25.5% 26.0% • Revenue: - Price increase for 2018 of c. 5.3% - Return to positive PPD growth - Complementary Services continues to s
Slide 11: Financial review: International
Financial review International Estimated Range 30 Sept 31 Mar 31 Mar 2018 2017 2017 Alliance Medical: (£) Revenue % growth 7.0% to 9.0% 12.0% 5.0% Normalised EBITDA margin % 21.0% to 23.0% 23.8% 27.7% Scanmed: (PLN) Revenue % growth 4.0% to 6.0% -6.7% - 7.3% Normalised EBITDA margin % 7.5% to 9.0% 4
Slide 12: Financial review: Group
Financial review Group Estimated Range 30 Sept 31 Mar 31 Mar 2018 2017 2017 Revenue % growth 16.5% to 18.5% 26.8% 22.6% Normalised EBITDA margin % 23.3% to 23.9% 24.0% 25.1% Average exchange rates – ZAR/GBP 17.4 – 17.7 16.93 16.72 Average exchange rates – ZAR/Zloty 3.65 – 3.80 3.44 3.35 EPS (Previou
Slide 13: 2018 Interim Results Schedule
2018 Interim Results Schedule Event Date Interim Results - SENS 07:00 (CAT), 1 June 2018 Interim Results 10:00 (CAT), 1 June 2018 Investor Road show - CALGEMS 5 / 6 June 2018 Investor road show - London 8 June 2018 Investor road show – Johannesburg 12 June 2018 Investor road show – Cape Town 13 June
Slide 14: Thank You
THANK YOU THIS UPDATE IS PROVIDED PRIOR TO RECEIVING THE MARCH 2018 OPERATIONAL AND FINANCIAL RESULTS. AS SUCH THE GUIDANCE PROVIDED MAY CHANGE AND SHOULD BE TREATED WITH THE NECESSARY CAUTION 14
Life Healthcare Group Holdings — Investor Presentation (March 2018) on 6ix